Similar articles for PMID: 33419944

Year	Number of Results
2011	1
2012	5
2013	5
2014	4
2015	6
2016	13
2017	15
2018	21
2019	22
2020	19
2021	18
2022	5

1

Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.

Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, Larson S, Scher HI, Vargas HA. Wibmer AG, et al. J Nucl Med. 2021 Aug 1;62(8):1050-1056. doi: 10.2967/jnumed.120.256602. Epub 2021 Jan 8. J Nucl Med. 2021. PMID: 33419944

2

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y. Zhang H, et al. Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19. Acad Radiol. 2013. PMID: 22999369

3

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y. Liao S, et al. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23. Eur J Nucl Med Mol Imaging. 2012. PMID: 21946983

4

Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.

Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, Pandey AK, Sekhar Bal C, Patel CD, Sharma P, Agarwal KK, Kumar R. Sharma A, et al. Clin Nucl Med. 2018 Jan;43(1):e8-e17. doi: 10.1097/RLU.0000000000001886. Clin Nucl Med. 2018. PMID: 29112011

5

Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.

Woff E, Hendlisz A, Ameye L, Garcia C, Kamoun T, Guiot T, Paesmans M, Flamen P. Woff E, et al. J Nucl Med. 2019 Feb 1;60(2):178-184. doi: 10.2967/jnumed.118.210161. Epub 2018 Jun 29. J Nucl Med. 2019. PMID: 29959212 Free article.

6

Harmonized pretreatment quantitative volume-based ¹⁸F-FDG PET/CT parameters for stage IV breast cancer prognosis. Multicenter study in Japan.

Kitajima K, Miyoshi Y, Sekine T, Takei H, Ito K, Suto A, Kaida H, Daisaki H, Yamakado K. Kitajima K, et al. Hell J Nucl Med. 2020 Sep-Dec;23(3):272-289. doi: 10.1967/s002449912218. Hell J Nucl Med. 2020. PMID: 33367302 Free article.

7

Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.

Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J. Son SH, et al. AJR Am J Roentgenol. 2015 Oct;205(4):878-85. doi: 10.2214/AJR.14.13906. Epub 2015 Jul 23. AJR Am J Roentgenol. 2015. PMID: 26204115

8

Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.

Calles-Sastre L, Mucientes-Rasilla J, San-Frutos Llorente LM, Royuela A, Garcia-Espantaleón Navas M, Herrero Gámiz S, Pérez-Medina T. Calles-Sastre L, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Jan-Feb;38(1):17-21. doi: 10.1016/j.remn.2018.08.001. Epub 2018 Oct 23. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019. PMID: 30366731 English, Spanish.

9

The prognostic value of volume-based parameters using ¹⁸F-FDG PET/CT in gastric cancer according to HER2 status.

Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. Park JS, et al. Gastric Cancer. 2018 Mar;21(2):213-224. doi: 10.1007/s10120-017-0739-0. Epub 2017 Jun 22. Gastric Cancer. 2018. PMID: 28643145

10

Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F. Caroli P, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6. Eur J Nucl Med Mol Imaging. 2018. PMID: 29110067 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed